Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mexiletine for Motor Dysfunction in SBMA
NCT06862596Phase 3Recruiting
- Start
- Feb 2025
- Primary completion
- Dec 2027
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of mexiletine in spinal and bulbar muscular atrophy (SBMA). Started Feb 2025; status: recruiting.
02
Drugs
mexiletine
03
Conditions
spinal and bulbar muscular atrophy (SBMA)
Beyond the preview
Go deeper on NCT06862596.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06862596.